ADTX Key Statistics, Chart & Performance
The current stock price of ADTX is 0.865 USD. In the past month the price decreased by -71.35%. In the past year, price decreased by -99.98%.
ADTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.26 | 405.17B | ||
| AMGN | AMGEN INC | 15.52 | 182.73B | ||
| GILD | GILEAD SCIENCES INC | 15.02 | 152.59B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.85 | 122.65B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.85 | 84.44B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 827.62 | 55.76B | ||
| INSM | INSMED INC | N/A | 37.01B | ||
| NTRA | NATERA INC | N/A | 35.27B | ||
| BIIB | BIOGEN INC | 11.03 | 27.07B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.03 | 21.62B | ||
| INCY | INCYTE CORP | 17.26 | 21.76B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.30B |
Related stock screener links
About ADTX
Company Profile
Aditxt Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Richmond, Virginia and currently employs 26 full-time employees. The company went IPO on 2020-06-19. Aditxt, Inc. is a social innovation platform dedicated to accelerating promising health innovations. The company develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. The company also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.
Company Info
ADITXT INC
737 N. Fifth Street, Suite 200
Richmond VIRGINIA 94043 US
CEO: Amro Albanna
Employees: 26
Phone: 19094880844
ADITXT INC / ADTX FAQ
What does ADTX do?
Aditxt Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Richmond, Virginia and currently employs 26 full-time employees. The company went IPO on 2020-06-19. Aditxt, Inc. is a social innovation platform dedicated to accelerating promising health innovations. The company develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. The company also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.
What is the current price of ADTX stock?
The current stock price of ADTX is 0.865 USD. The price decreased by -1.7% in the last trading session.
Does ADITXT INC pay dividends?
ADTX does not pay a dividend.
How is the ChartMill rating for ADITXT INC?
ADTX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Which stock exchange lists ADTX stock?
ADTX stock is listed on the Nasdaq exchange.
What is the market capitalization of ADTX stock?
ADITXT INC (ADTX) has a market capitalization of 484.40K USD. This makes ADTX a Nano Cap stock.
What is the Short Interest ratio of ADITXT INC (ADTX) stock?
The outstanding short interest for ADITXT INC (ADTX) is 15.47% of its float.
ADTX Technical Analysis
ADTX Financial Highlights
Over the last trailing twelve months ADTX reported a non-GAAP Earnings per Share(EPS) of -13217.71. The EPS increased by 81.34% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -357.97% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ADTX Forecast & Estimates
For the next year, analysts expect an EPS growth of -2096.63% and a revenue growth 1584.79% for ADTX